<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625791</url>
  </required_header>
  <id_info>
    <org_study_id>PREDISARC</org_study_id>
    <nct_id>NCT03625791</nct_id>
  </id_info>
  <brief_title>Validation of a Genetic Signature to Predict the Development of Sarcomas</brief_title>
  <acronym>PREDISARC</acronym>
  <official_title>Validation of a Genetic Signature to Predict the Development of Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the SARI study was to describe biomarkers of predisposition to the development of
      sarcomas in irradiated territory. This study included 120 patients with sarcoma in irradiated
      territory and 240 patients who had been treated with radiotherapy for more than 5 years and
      had not developed sarcoma.

      Following the sequencing of the exomes of all these patients, the SARI study made it possible
      to highlight a genetic signature from 11 genes, predictive of the appearance of a sarcoma
      after a first radiotherapy. This signature is the subject of a patent (BFF 170286 / VF, filed
      on June 22, 2017). A final validation step with samples that have not been used to optimize
      this signature is now required. Moreover, it is now necessary to validate if this signature
      is specific to the predisposition to the development of radiation-induced sarcomas only or if
      this signature is also valid for the predisposition to the development of all sarcomas, even
      primary ones.

      The objective of the PREDISARC study is to evaluate the specificity of this genetic signature
      (11 genes) with the appearance of sarcomas in irradiated territory compared to a population
      without sarcoma that has been treated with radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 60 patients will be included in this pilot study:

        -  Group 1: 20 patients with induced radio sarcoma

        -  Group 2: 20 patients without primary sarcoma or induced radio sarcoma

        -  Group 3: 20 patients with primary sarcoma These numbers will make it possible to have
           preliminary data making it possible to judge the interest of the genetic signature in
           the prediction of the radiation-induced sarcomas.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 19, 2020</completion_date>
  <primary_completion_date type="Actual">June 19, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DNA</measure>
    <time_frame>at the inclusion</time_frame>
    <description>Bioinformatic analyzes will be realized out blindly on the 11 genes of the signature to validate determining the group of belonging of the patients</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Genetic Signature in Development of Sarcomas</condition>
  <arm_group>
    <arm_group_label>radiation-induced sarcomas</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>radiotherapy for at least 5 years and without sarcomas</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>primary sarcomas</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>1 tube with 4 ml of blood per patient</description>
    <arm_group_label>primary sarcomas</arm_group_label>
    <arm_group_label>radiation-induced sarcomas</arm_group_label>
    <arm_group_label>radiotherapy for at least 5 years and without sarcomas</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Group 1: 20 patients with sarcoma developed in irradiated territory

          -  Group 2: 20 patients treated for cancer by radiotherapy for more than 5 years and who
             have not developed sarcoma

          -  Group 3: 20 patients with primary sarcoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Major patient at the time of initial radiotherapy or diagnosis of primary sarcoma.

          2. Patient belonging to one of these 3 groups :

             Group 1: Patient treated with radiotherapy for cancer other than primary sarcoma and
             who developed sarcoma (other than osteosarcoma) in the irradiated area.

             OR Group 2: Patient who received radiotherapy for more than 5 years and did not
             develop sarcoma or other secondary cancers OR Group 3: Patient who developed primary
             sarcoma and who had never been treated with radiotherapy

          3. Patient who have signed informed consent to participate in the study.

          4. Affiliation to the social security system.

        Exclusion Criteria:

          1. Patient unable to understand, read and / or sign informed consent.

          2. Person benefiting from a protection system for adults (including guardianship and
             trusteeship)

          3. Pregnant or lactating woman.

          4. Patient who participated in the SARI study &quot;Predictive study of sarcomas developed in
             irradiated territory from the GSF-GETO database (ID-RCB no .: 2011-A01102-39)&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles TRUC</last_name>
    <role>Principal Investigator</role>
    <affiliation>CGFL, Dijon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles TRUC, PU PH</last_name>
    <phone>03 80 73 75 18</phone>
    <email>gtruc@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie REDERSTORFF</last_name>
    <phone>03 45 34 81 16</phone>
    <email>erederstorff@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institu Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul SARGOS</last_name>
      <phone>05 56 33 33 43</phone>
      <email>p.sargos@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles TRUC</last_name>
      <phone>03 80 73 75 18</phone>
      <email>gtruc@cgfl.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilie REDERSTORFF</last_name>
      <phone>03 45 34 81 16</phone>
      <email>erederstorff@cgfl.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Gilles TRUC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine PEIGNAUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David THIBOUW</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas ISAMBERT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice HERVIEU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain CAUSERET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean FRAISSE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile LE PECHOUX</last_name>
      <phone>01 42 11 47 57</phone>
      <email>cecile.lepechoux@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sarcoma</keyword>
  <keyword>genetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

